CJC-1295 No-DAC vs Traditional CJC-1295: A Preclinical Research Comparison

Among growth hormone-releasing hormone (GHRH) analogs studied in peptide research, two compounds often appear side by side: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 No-DAC, also known as Modified GRF 1-29 or Mod GRF 1-29. Though both share a structural origin in the first 29 amino acids of endogenous GHRH, their pharmacokinetic profiles diverge substantially due to a single design difference – the presence or absence of albumin-binding technology. Understanding how researchers distinguish these two analogs requires a close look at the underlying biochemistry and what preclinical studies have revealed.

Structural Origins: GHRH(1-29) as the Common Framework

Endogenous human growth hormone-releasing hormone (hGRF) is a 44-amino acid neuropeptide produced in the hypothalamus. Its first 29 residues – hGRF(1-29) – retain full receptor binding activity at the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. However, native hGRF(1-29) is rapidly degraded in plasma by dipeptidyl peptidase IV (DPP-IV) and other enzymes, giving it a half-life of only a few minutes under physiological conditions.

Research published in Endocrinology (PMID: 15817669) by Jetté et al. described the development of stabilized hGRF(1-29) analogs incorporating amino acid substitutions at positions susceptible to enzymatic cleavage – particularly at position 2 (Ala→Aib) and position 8 (Asn→Gln). These substitutions form the basis of what is now called Modified GRF 1-29 (CJC-1295 No-DAC). The result is a GHRH analog with improved plasma stability, capable of activating the GHRH receptor over a longer window – estimated at 30 minutes to 2 hours in research models – compared with native hGRF(1-29).

The DAC Mechanism: Albumin Bioconjugation for Extended Half-Life

CJC-1295 with DAC takes the stabilization a step further by incorporating a reactive maleimide group – the Drug Affinity Complex – that enables the peptide to covalently bind the free thiol on Cys34 of circulating serum albumin after administration. This reaction effectively converts the peptide into a long-circulating albumin-bound depot.

The same Endocrinology study (PMID: 15817669) demonstrated that this in vivo bioconjugation strategy could extend GRF analog half-life to an estimated 5.8 days in rats, compared with minutes for native hGRF. Follow-up research by Teichman et al. published in the Journal of Clinical Endocrinology & Metabolism (PMID: 16352683) characterized the GH and IGF-1 secretion profiles associated with CJC-1295 (with DAC) over extended time intervals, documenting sustained elevations in GH area-under-curve and IGF-1 levels maintained across multi-day windows in research subjects.

Pulsatile Secretion: A Key Mechanistic Question

One concern with any long-acting GHRH analog is whether continuous receptor stimulation disrupts the physiological pulsatile pattern of GH secretion. This is not a trivial question – pulsatility is central to how somatotroph cells maintain sensitivity and downstream IGF-1 axis function.

Research by Ionescu and Frohman published in JCEM (PMID: 17018654) investigated this directly, finding that pulsatile GH secretion persisted during continuous CJC-1295 (with DAC) stimulation in research models. The authors observed that despite sustained GHRH receptor engagement, the somatotroph axis continued to exhibit episodic GH release, a finding attributed to the preserved influence of somatostatin (SST) counterregulation. This result has been important for understanding how long-acting GHRH analogs interact with the hypothalamic-pituitary axis at a systems level.

A related study by Alba and colleagues (PMID: 16822960) examined once-daily CJC-1295 administration in GHRH knockout mice, a model of severe GH deficiency. The research observed normalization of growth curves in these animals, providing a mechanistic context for how sustained GHRH receptor activation can support somatotroph function in preclinical deficiency models.

Key Distinctions for Researchers

The fundamental research distinction between the two variants comes down to kinetics:

• CJC-1295 No-DAC (Mod GRF 1-29): Acts as a pulse-mimicking GHRH analog. Its shorter active window (approximately 30 minutes to 2 hours) allows researchers to study time-gated GH secretion events and interactions with co-administered growth hormone secretagogues such as Ipamorelin or GHRP-2. This makes it a common choice in research designs investigating pulsatile GH dynamics and receptor co-stimulation.
• CJC-1295 with DAC: Designed for sustained GHRH receptor engagement over days. Research uses it to study chronic GH/IGF-1 axis activation, trophic effects on somatotroph cells, and GH deficiency models requiring prolonged receptor stimulation. Its albumin binding means it is detected and studied over multi-day timescales.

Additional work catalogued in the literature (PMID: 19386527) has examined IGF-1 axis activation profiles associated with long-acting GHRH analogs, providing further mechanistic insight into downstream signaling cascades initiated by sustained GHRHR engagement – including JAK2/STAT5, MAPK, and PI3K/Akt pathways in somatotroph and hepatic cell models.

Frequently Asked Questions

What is the difference between CJC-1295 No-DAC and CJC-1295 with DAC?

CJC-1295 No-DAC (Modified GRF 1-29) is a stabilized GHRH analog with an active window of approximately 30 minutes to 2 hours. CJC-1295 with DAC incorporates albumin-binding technology that extends its plasma half-life to approximately 6–8 days in preclinical models, enabling sustained GHRH receptor activation studied over multi-day intervals.

How does CJC-1295 with DAC extend its half-life in research models?

It uses a reactive maleimide group (the Drug Affinity Complex) that covalently binds to Cys34 on serum albumin after administration, creating a long-circulating depot that is slowly released. This mechanism was characterized in research published in Endocrinology (PMID: 15817669).

Does CJC-1295 preserve pulsatile GH secretion in preclinical models?

Yes – a study published in JCEM (PMID: 17018654) observed that pulsatile GH secretion persisted during continuous CJC-1295 stimulation, attributed to intact somatostatin counterregulation maintaining episodic GH release patterns.

What is Mod GRF 1-29 (CJC-1295 No-DAC) used for in research?

Researchers use it to study pulsatile GHRH receptor activation, somatotroph signaling, and GH/IGF-1 axis regulation. Its shorter action window makes it suited for studies examining acute GH pulse dynamics and receptor co-stimulation paradigms.

Is CJC-1295 No-DAC available for research sourcing?

Core Research Peptides supplies CJC-1295 No-DAC (Modified GRF 1-29) as a third-party tested, research-grade compound. All products are for laboratory use only and are accompanied by a Certificate of Analysis. Not for human consumption.

References

1. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. PMID: 15817669
2. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. PMID: 17018654
4. Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290–E1294. PMID: 16822960
5. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471–477. PMID: 19386527